Related Experiment Video
Updated: May 13, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation
Kristin Dawson1, Reza Wakili, Balázs Ordög
1Montreal Heart Institute Research Center, 5000 Belanger St E, Montreal, Quebec, H1T 1C8, Canada.
Background:
Congestive heart failure (CHF) causes atrial fibrotic remodeling, a substrate for atrial fibrillation (AF) maintenance. MicroRNA29 (miR29) targets extracellular matrix proteins. In the present study, we examined miR29b changes in patients with AF and/or CHF and in a CHF-related AF animal model and assessed its potential role in controlling atrial fibrous tissue production.
Methods And Results:
Control dogs were compared with dogs subjected to ventricular tachypacing for 24 hours, 1 week, or 2 weeks to induce CHF. Atrial miR29b expression decreased within 24 hours in both whole atrial tissue and atrial fibroblasts (-87% and -92% versus control, respectively; p<0.001 for both) and remained decreased throughout the time course. Expression of miR29b extracellular matrix target genes collagen-1A1 (COL1A1), collagen-3A1 (COL3A1), and fibrillin increased significantly in CHF fibroblasts. Lentivirus-mediated miR29b knockdown in canine atrial fibroblasts (-68%; p<0.01) enhanced COL1A1, COL3A1, and fibrillin mRNA expression by 28% (p<0.01), 19% (p<0.05), and 20% (p<0.05), respectively, versus empty virus-infected fibroblasts and increased COL1A1 protein expression by 90% (p<0.05). In contrast, 3-fold overexpression of miR29b decreased COL1A1, COL3A1, and fibrillin mRNA by 65%, 62%, and 61% (all p<0.001), respectively, versus scrambled control and decreased COL1A1 protein by 60% (p<0.05). MiR29b plasma levels were decreased in patients with CHF or AF (by 53% and 54%, respectively; both p<0.001) and were further decreased in patients with both AF and CHF (by 84%; p<0.001). MiR29b expression was also reduced in the atria of chronic AF patients (by 54% versus sinus rhythm; p<0.05). Adenoassociated viral-mediated knockdown of miR29b in mice significantly increased atrial COL1A1 mRNA expression and cardiac tissue collagen content.
Conclusions:
MiR29 likely plays a role in atrial fibrotic remodeling and may have value as a biomarker and/or therapeutic target.
Insights
Congestive heart failure and atrial fibrillation reduce microRNA29b (miR29b) levels, promoting atrial fibrosis. Restoring miR29b may combat fibrotic remodeling in heart conditions.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Biomarker Discovery
Background:
- Congestive heart failure (CHF) induces atrial fibrotic remodeling, supporting atrial fibrillation (AF) maintenance.
- MicroRNA29 (miR29) is a key regulator of extracellular matrix proteins.
- Investigating miR29b in AF and CHF is crucial for understanding atrial fibrosis.
Purpose of the Study:
- To examine miR29b expression changes in patients and animal models of AF and CHF.
- To assess the role of miR29b in regulating atrial fibrotic tissue production.
- To evaluate miR29b as a potential biomarker and therapeutic target.
Main Methods:
- Induction of CHF in a canine model via ventricular tachypacing.
- Measurement of atrial miR29b expression and extracellular matrix gene expression (COL1A1, COL3A1, fibrillin) in fibroblasts.
- In vivo manipulation of miR29b levels using lentiviral and adenoassociated viral vectors.
- Quantification of plasma miR29b levels in patients with CHF and/or AF.
Main Results:
- Atrial miR29b expression significantly decreased within 24 hours of CHF induction in dogs.
- miR29b knockdown in fibroblasts increased collagen and fibrillin expression; miR29b overexpression decreased them.
- Plasma miR29b levels were markedly reduced in patients with CHF or AF, and even lower in those with both conditions.
- miR29b knockdown in mice led to increased atrial collagen content.
Conclusions:
- MiR29b plays a significant role in atrial fibrotic remodeling associated with CHF and AF.
- Reduced miR29b levels are a hallmark of these cardiac conditions.
- MiR29b holds potential as a diagnostic biomarker and a therapeutic target for atrial fibrosis.
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs

